ストックスクリーナーアプリを入手
338.11
0.24%
-0.80
アフターアワーズ：
338.11
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
Madrigal signals blockbuster Rezdiffra trajectory as new patent extends exclusivity to 2045 - MSN
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN
Madrigal Pharmaceuticals: Strategic Growth and Market Potential Driven by Rezdiffra’s Success and Key Acquisitions - TipRanks
Madrigal Pharmaceuticals (MDGL) Stock Target Raised on Strong 2Q Results - GuruFocus
Madrigal 2025 Q2 Earnings Strong Revenue Surge, Narrowed Losses - AInvest
Madrigal: Q2 Earnings Snapshot - New Haven Register
Madrigal Pharmaceuticals Inc (MDGL) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Madrigal (MDGL) Q2 Revenue Soars 1,313% - AOL.com
Madrigal Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Madrigal Surges 8.59 on 290th-Ranked $410M Volume as Patent Extensions and $212M Rezdiffra Sales Drive Momentum - AInvest
Madrigal Pharmaceuticals (MDGL) Achieves Key Growth Milestones w - GuruFocus
Madrigal Pharmaceuticals' Q2 2025: Contradictions Surrounding GLP-1 Market Impact and Rezdiffra Growth - AInvest
Madrigal Pharmaceuticals stock surges as Goldman reiterates buy on strong sales - Investing.com Canada
Madrigal Pharmaceuticals to Announce Q2 2025 Results with Live Webcast - MSN
Madrigal (MDGL) Q2 Revenue Soars 1,313% - The Motley Fool
Madrigal stock jumps after massive Q2 beat (MDGL:NASDAQ) - Seeking Alpha
Madrigal’s MASH drug handily tops forecasts as execs discuss GLP-1 combos - Endpoints News
GLP-1, Rezdiffra MASH-up eyed in $2B Madrigal/CSPC deal - BioWorld MedTech
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Madrigal Pharmaceuticals Q2 Financial Results Exceed ExpectationsNews and Statistics - IndexBox
Madrigal Pharmaceuticals' Q2 2025 Earnings Signal a Pivotal Moment for Long-Term Value Creation - AInvest
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
China momentum continues with Madrigal-CSPC, Arrowhead- Sanofi tie-ups: Deals Report - BioCentury
How strong is Madrigal Pharmaceuticals Inc. company’s balance sheetOutstanding capital growth - Jammu Links News
Is Madrigal Pharmaceuticals Inc. stock overvalued or undervaluedInvest smarter with advanced market data - Jammu Links News
Is Madrigal Pharmaceuticals Inc. a growth stock or a value stockHigh-profit trading signals - Jammu Links News
How does Madrigal Pharmaceuticals Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
How volatile is Madrigal Pharmaceuticals Inc. stock compared to the marketBuild wealth with reliable stock picks - Jammu Links News
West Conshohocken’s Madrigal Pharmaceuticals Gets FDA Green Light - MSN
What are Madrigal Pharmaceuticals Inc. company’s key revenue driversInvest confidently with market-leading analysis - Jammu Links News
Does Madrigal Pharmaceuticals Inc. stock perform well during market downturnsSuperior trading gains - Jammu Links News
What is the dividend policy of Madrigal Pharmaceuticals Inc. stockBuild wealth faster with expert stock selection - Jammu Links News
Is Madrigal Pharmaceuticals Inc. a good long term investmentUnlock your portfolio’s hidden potential - Jammu Links News
What makes Madrigal Pharmaceuticals Inc. stock price move sharplyMaximize your returns with smart trade entries - Jammu Links News
The week in pharma: action, reaction and insight – week to August 1 - The Pharma Letter
Published on: 2025-08-03 13:27:37 - Jammu Links News
When is Madrigal Pharmaceuticals Inc. stock expected to show significant growthDiscover hidden gems in the stock market - Jammu Links News
What are analysts’ price targets for Madrigal Pharmaceuticals Inc. in the next 12 monthsExceptional risk-adjusted gains - Jammu Links News
Should I hold or sell Madrigal Pharmaceuticals Inc. stock in 2025Access daily stock market expert updates - Jammu Links News
What are the technical indicators suggesting about Madrigal Pharmaceuticals Inc.Market Forecast Opportunities Backed By Experts - Jammu Links News
Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term (MDGL) - Seeking Alpha
Madrigal in-pact with CSPC Pharma for obesity drug license - MSN
Analyzing recovery setups for Madrigal Pharmaceuticals Inc. investorsSwing Trade Entry With Volume Triggers Released - metal.it
Non-Alcoholic Steatohepatitis Market Set to Grow - openPR.com
Madrigal Pharmaceuticals Enters into Exclusive Global - GlobeNewswire
Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN
Madrigal Pharmaceuticals' Strategic Licensing Deal: A Pivotal Move in the NASH Therapeutics Arms Race - AInvest
Madrigal inks license deal with CSPC Pharma - The Pharma Letter
Madrigal in-pact with CSPC Pharma for GLP-1 candidate license - Seeking Alpha
0.10%
0.21%
大文字化:
|
ボリューム (24 時間):